Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis

Charite University, Berlin, Germany100 enrolled

Overview

Impairment of visual deficits, in particular contrast acuity and contrast impairment are frequent symptoms in MS. However, visual function is not appropriately covered by the standard tools for clinical assessment, namely, the EDSS and the MSFC. The primary aim of this study is to investigate, whether in MS patients contrast acuity and sensitivity change over a period of two years. Secondary aims are the correlation of visual contrast parameters with structural retinal changes and quality of life.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Multiple Sclerosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically Isolated Syndrome or definite MS (relapsing-remitting or secondary progressive course) * Written Informed Consent Exclusion Criteria: * Relapse within the last 30 Days * Significant Cognitive Impairment * Severely Decreased Visual Acuity * Preexisting Severe Retinal Pathology

Locations (1)

NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin

Berlin, Germany

Outcomes

Primary Outcomes

Visual Contrast Acuity

Time frame: 24 Months

Secondary Outcomes

Structural and Functional Changes of Optic Pathway

Time frame: 24 Months

Clinical Neurological Assessment

Time frame: 24 Months

Quality of Life

Time frame: 24 Months

Contrast Sensitivity

Time frame: 24 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.